Abstract
Background: Recent reports describe discontinuation-emergent adverse events upon cessation
of selective serotonin reuptake inhibitors including dizziness, insomnia, nervousness,
nausea, and agitation. We hypothesized that interruption of fluoxetine treatment would
be associated with fewer discontinuation-emergent adverse events than interruption
of sertraline or paroxetine treatment, based on fluoxetine’s longer half-life.
Methods: In this 4-week study, 242 patients with remitted depression receiving maintenance
therapy with open-label fluoxetine, sertraline, or paroxetine for 4–24 months had
their maintenance therapy interrupted with double-blind placebo substitution for 5–8
days. The Symptom Questionnaire (SQ), the Discontinuation-Emergent Signs and Symptoms
checklist, the 28-item Hamilton Depression Rating Scale, and the Montgomery–Asberg
Depression Rating Scale were used to assess somatic distress and stability of antidepressant
response.
Results: Two hundred twenty patients (91%) completed the study. Following interruption
of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent
events than either sertraline-treated or paroxetine-treated patients (p < .001). The mean SQ somatic symptom scale score in fluoxetine-treated patients was
significantly lower than that in sertraline-treated and paroxetine-treated patients
(p < .001). Fluoxetine-treated patients also experienced less reemergence of depressive
symptoms than sertraline-treated or paroxetine-treated patients (p < .001).
Conclusions: Abrupt interruption of antidepressant therapy for 5–8 days was associated
with the emergence of new somatic and psychological symptoms in patients treated with
paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Physical symptoms associated with paroxetine discontinuation [letter].Am J Psychiatry. 1994; 151: 289
- Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders [letter].Hum Psychopharmacol. 1996; 11: 337-338
- Patient compliance and medication perception.J Clin Psychol. 1986; 42: 49-53
- Antidepressant withdrawal.Am J Psychiatry. 1993; 150: 165
- Abrupt discontinuation of tricyclic antidepressant drugs.Br J Psychiatry. 1982; 141: 377-386
- Serotonin reuptake inhibitor withdrawal.J Clin Psychopharmacol. 1996; 16: 356-362
- Compliance in depressed patients treated with fluoxetine or amitriptyline.Int Clin Psychopharmacol. 1997; 13: 11-17
- Antidepressant withdrawal phenomena.Biol Psychiatry. 1984; 19: 237-256
- Antidepressant withdrawal symptoms treated with anticholinergic agents.Am J Psychiatry. 1983; 140: 249-251
- Antidepressant withdrawal syndromes.Int Clin Psychopharmacol. 1987; 2: 1-19
- Fluoxetine withdrawal? [letter].Am J Psychiatry. 1995; 152: 1235
- Withdrawal syndromes after paroxetine and sertaline discontinuation [letter].J Clin Psychopharmacol. 1995; 15: 374-375
- Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter].Am J Psychiatry. 1995; 152: 810
Gillespie C, Wildgust HJ, Haddad P, Currie A (1996): SSRIs and withdrawal syndrome [abstract]. World Congress of Psychiatry, Madrid, August 23–28.
- A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
- Reversible delirium after discontinuation of fluoxetine.J Med Assoc Thai. 1995; 78: 53-54
- A symptom questionnaire.J Clin Psychiatry. 1987; 48: 268-274
- The development of sensitive scales for research in therapeutics.in: Fava M Rosenbaum J.F Research Designs and Methods in Psychiatry. Elsevier, New York1992: 213-222
- Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter].J Clin Psychopharmacol. 1994; 14: 206-207
- Paroxetine induced withdrawal effects.Hum Psychopharmacol. 1995; 10: 147-148
- Potential withdrawal syndrome associated with SSRI discontinuation.Ann Pharmacother. 1995; 29: 1284-1285
Lejoyeux M, Adès J, Mourad I, Solomon J, Dilsaver S (1996): Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 278–292.
- Discontinuation reactions following sertraline.Biol Psychiatry. 1995; 38: 694-695
- Withdrawal reaction after sertraline discontinuation [letter].Am J Psychiatry. 1994; 151: 450-451
- Is there a serotonergic withdrawal syndrome? [letter].Biol Psychiatry. 1993; 33: 851-852
- A new depression scale designed to be sensitive to change.Br J Psychiatry. 1979; 134: 382-389
- Selective serotonin reuptake inhibitors.Int Clin Psychopharmacol. 1994; 9: 47-53
- Paroxetine in the treatment of panic disorder.Br J Psychiatry. 1995; 167: 374-379
- Facteurs psychologiques, observance et resistance aux traitements antidepresseurs (Psychological factors, compliance and resistance to antidepressant treatment) (abstract in English).Encephale. 1986; 12: 197-203
- Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells.Psychopharmacology (Berl). 1982; 76: 26-28
- A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.Br J Clin Pharmacol. 1996; 42: 757-763
- Paroxetine withdrawal syndromes (letter).Am J Psychiatry. 1995; 152: 149-150
- Selective serotonin reuptake inhibitor-induced sexual dysfunction.Am J Psychiatry. 1995; 152: 1514-1516
- Extrapyramidal symptoms upon discontinuation of fluoxetine (letter).Am J Psychiatry. 1991; 148: 1263
- Patterns of antidepressant use and their relation to costs of care.Am J Managed Care. 1996; 2: 1239-1246
- A comparison of peripheral and central human muscarinic receptor affinities for psychotropic drugs.Biol Psychiatry. 1982; 17: 555-567
- Clinical pharmacokinetics of selective serotonin reuptake inhibitors.Clin Pharmacokinet. 1993; 24: 203-220
- Medication noncompliance in schizophrenia.Bull Am Acad Psychiatry Law. 1986; 14: 105-122
- Safety of abrupt discontinuation of fluoxetine.J Clin Psychopharmacol. 1998; 18: 193-197
Article info
Publication history
Accepted:
March 24,
1998
Received in revised form:
March 18,
1998
Received:
November 18,
1997
Identification
Copyright
© 1998 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
